It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Female genital tract (FGT) inflammation increases HIV infection susceptibility. Non-optimal cervicovaginal microbiota, characterized by depletion of Lactobacillus species and increased bacterial diversity, is associated with increased FGT cytokine production. Lactobacillus species may protect against HIV partly by reducing FGT inflammation. We isolated 80 lactobacilli from South African women with non-optimal (Nugent 4–10; n = 18) and optimal microbiota (Nugent 0–3; n = 14). Cytokine production by vaginal epithelial cells in response to lactobacilli in the presence and absence of Gardnerella vaginalis was measured using Luminex. Adhesion to vaginal epithelial cells, pH, D/L-lactate production and lactate dehydrogenase relative abundance were assessed. Lactobacilli from women with non-optimal produced less lactic acid and induced greater inflammatory cytokine production than those from women with optimal microbiota, with IL-6, IL-8, IL-1α, IL-1β and MIP-1α/β production significantly elevated. Overall, lactobacilli suppressed IL-6 (adjusted p < 0.001) and IL-8 (adjusted p = 0.0170) responses to G. vaginalis. Cytokine responses to the lactobacilli were inversely associated with lactobacilli adhesion to epithelial cells and D-lactate dehydrogenase relative abundance. Thus, while cervicovaginal lactobacilli reduced the production of the majority of inflammatory cytokines in response to G. vaginalis, isolates from women with non-optimal microbiota were more inflammatory and produced less lactic acid than isolates from women with optimal microbiota.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM), Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151)
2 UMR 5290 MIVEGEC, French National Centre for Scientific Research (CNRS), Montpellier, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282)
3 University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM), Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151); University of Washington, Seattle Children’s Research Institute, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM), Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151); University of Cape Town, Desmond Tutu HIV Centre, Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151)
5 University of the Witwatersrand, Perinatal HIV Research Unit, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135); South African Medical Research Council, Cape Town, South Africa (GRID:grid.415021.3) (ISNI:0000 0000 9155 0024)
6 University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM), Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151); Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa (GRID:grid.428428.0) (ISNI:0000 0004 5938 4248); National Health Laboratory Service, Cape Town, South Africa (GRID:grid.416657.7) (ISNI:0000 0004 0630 4574)
7 University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM), Cape Town, South Africa (GRID:grid.7836.a) (ISNI:0000 0004 1937 1151); Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa (GRID:grid.428428.0) (ISNI:0000 0004 5938 4248); Disease Elimination Program, Life Sciences Discipline, Burnet Institute, Melbourne, Australia (GRID:grid.1056.2) (ISNI:0000 0001 2224 8486)